Comparison of Lipid Results From 2007 to 2009 via Commercial Clinical Laboratory Testing Versus a Population-Based Cohort: Proof-of-Concept for Population Health Monitoring of Lipids Using Commercial Lab Data

BACKGROUND: Large commercial laboratories serve millions of patients and generate billions of test results annually. The objective of our study was to assess the potential use of commercial laboratory lipid testing for population health monitoring. METHODS: codes listing diabetes or cardiovascular disease as the indication for testing. The associations between abnormal lipid levels (high-density lipoprotein cholesterol <50 mg/dL in women and <40 mg/dL in men, low-density lipoprotein cholesterol ≥130 mg/dL, triglycerides ≥150 mg/dL) and residency in any of 76 ZIP codes was assessed in the commercial laboratory population using logistic regression adjusting for age and sex. RESULTS: The distribution plots of high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides were broadly similar in a commercial laboratory population (n=59 419; median age [interquartile range], 48 [33-58] years; 56% women) and DHS-2 (n=3147; median age [interquartile range], 50 [42-58] years; 60% women). Median high-density lipoprotein cholesterol was 1 mg/dL lower (95% CI 0.6-2), low-density lipoprotein cholesterol was 5 mg/dL lower (95% CI 3-6), and triglycerides were 12 mg/dL higher (95% CI 9-14) in the commercial laboratory population versus DHS-2. Similar results were observed in a sensitivity analysis that excluded those with diabetes or cardiovascular disease. Higher probabilities of abnormal levels of all 3 lipids were observed for 5 ZIP codes (odds ratios [95% CI] ranged from 1.07 [1.001-1.15] to 1.84 [1.48-2.28]). CONCLUSIONS: Within the same geographic region, the differences between lipids observed in commercial laboratory testing and in a population-based cohort were negligible (high-density lipoprotein cholesterol) to moderate (low-density lipoprotein cholesterol, triglycerides). This proof-of-concept study suggests that commercial laboratory testing may be useful for monitoring population lipid levels and assessing regional and temporal variation.

Authors

Institutions

Publication Details

Journal
Circulation Population Health and Outcomes
Published
2026-07-30
DOI
https://doi.org/10.1161/circoutcomes.126.013500
Primary Topic
Diabetes, Cardiovascular Risks, and Lipoproteins
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparison of Lipid Results From 2007 to 2009 via Commercial Clinical Laboratory Testing Versus a Population-Based Cohort: Proof-of-Concept for Population Health Monitoring of Lipids Using Commercial Lab Data

Jarett D. Berry, Dov Shiffman, Amil M. Shah, James A. de Lemos et al.
Circulation Population Health and Outcomes
Diabetes, Cardiovascular Risks, and Lipoproteins
article

Comparison of Lipid Results From 2007 to 2009 via Commercial Clinical Laboratory Testing Versus a Population-Based Cohort: Proof-of-Concept for Population Health Monitoring of Lipids Using Commercial Lab Data

Jarett D. Berry, Dov Shiffman, Amil M. Shah, James A. de Lemos, Michael J. McPhaul, Judy Z. Louie
article en

Abstract

BACKGROUND: Large commercial laboratories serve millions of patients and generate billions of test results annually. The objective of our study was to assess the potential use of commercial laboratory lipid testing for population health monitoring. METHODS: codes listing diabetes or cardiovascular disease as the indication for testing. The associations between abnormal lipid levels (high-density lipoprotein cholesterol <50 mg/dL in women and <40 mg/dL in men, low-density lipoprotein cholesterol ≥130 mg/dL, triglycerides ≥150 mg/dL) and residency in any of 76 ZIP codes was assessed in the commercial laboratory population using logistic regression adjusting for age and sex. RESULTS: The distribution plots of high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides were broadly similar in a commercial laboratory population (n=59 419; median age [interquartile range], 48 [33-58] years; 56% women) and DHS-2 (n=3147; median age [interquartile range], 50 [42-58] years; 60% women). Median high-density lipoprotein cholesterol was 1 mg/dL lower (95% CI 0.6-2), low-density lipoprotein cholesterol was 5 mg/dL lower (95% CI 3-6), and triglycerides were 12 mg/dL higher (95% CI 9-14) in the commercial laboratory population versus DHS-2. Similar results were observed in a sensitivity analysis that excluded those with diabetes or cardiovascular disease. Higher probabilities of abnormal levels of all 3 lipids were observed for 5 ZIP codes (odds ratios [95% CI] ranged from 1.07 [1.001-1.15] to 1.84 [1.48-2.28]). CONCLUSIONS: Within the same geographic region, the differences between lipids observed in commercial laboratory testing and in a population-based cohort were negligible (high-density lipoprotein cholesterol) to moderate (low-density lipoprotein cholesterol, triglycerides). This proof-of-concept study suggests that commercial laboratory testing may be useful for monitoring population lipid levels and assessing regional and temporal variation.

Circulation Population Health and Outcomes
The University of Texas at Tyler (US), Quest Diagnostics (United States) (US), The University of Texas Southwestern Medical Center (US)
Good health and well-being
Openalex Percentile: Top 9%
Diabetes, Cardiovascular Risks, and Lipoproteins
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.